Contextlogic Inc. Stock Price, News & Analysis

LogicBio Therapeutics (LOGC) reported interim data from the SUNRISE trial, showing detectable ALB-2A biomarkers in four pediatric patients indicating gene insertion success. Notably, two patients exhibited increasing ALB-2A levels, suggesting the expansion of edited cells. The proprietary mAAVRx manufacturing process demonstrated a 15-30 fold yield increase compared to standard methods. Financially, LOGC generated $3.2 million in collaboration revenue for Q2 2022, up from $0.8 million in Q2 2021, while net loss decreased to $5.0 million from $10.5 million year-over-year, with cash reserves of $38.8 million.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Frederic Chereau will present an overview at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The pre-recorded presentation will be available for on-demand viewing starting May 24, 2022, at 7:00 a.m. ET. A webcast of the presentation can be accessed on the company's website and will be available for approximately 30 days.

LogicBio focuses on genetic medicine, developing innovative genome editing and gene delivery platforms to address rare diseases.

LogicBio Therapeutics (NASDAQ: LOGC) announced the lifting of the FDA clinical hold on its SUNRISE trial for LB-001, a therapy for pediatric patients with methylmalonic acidemia (MMA). The company plans to resume patient dosing in Q3 2022, with interim clinical data expected by the end of Q2 2022. Financial results for Q1 2022 showed revenue of $2.8 million, an increase from $0.5 million in Q1 2021. R&D expenses decreased to $5.6 million from $6.4 million. The net loss narrowed to $6.7 million, or $0.20 per share, compared to a loss of $10.3 million, or $0.32 per share, in the previous year.

LogicBio Therapeutics (LOGC) announced the presentation of four abstracts at the ASGCT 2022 Annual Meeting from May 16-19, 2022, in Washington D.C. The presentations will cover the preclinical data of GeneRide LB-401, showing significant reduction in disease biomarkers for hereditary tyrosinemia type 1 (HT1). They also highlight advancements in AAV manufacturing, achieving a 15- to 30-fold yield increase and reducing manufacturing timelines from two weeks to four days. These innovations aim to enhance treatment efficacy and reduce manufacturing costs.

LogicBio Therapeutics (Nasdaq: LOGC) has announced that the FDA lifted the clinical hold on its LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia. The FDA's decision follows satisfactory resolutions of previous clinical hold issues, including two cases of thrombotic microangiopathy. The company plans to implement enhanced monitoring measures and resumes dosing by Q3 2022, with interim clinical data expected by the end of Q2 2022.

LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Frederic Chereau will present a company overview at the H.C. Wainwright Gene Therapy and Gene Editing Conference. The presentation will be available on demand starting at 7:00 a.m. ET on March 30, 2022. A webcast of the presentation can be accessed in the Investors section of the company's website, with a replay available for approximately 30 days. LogicBio focuses on genome editing and gene delivery for rare diseases, utilizing its GeneRide™ and sAAVy™ platforms.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Frederic Chereau will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:20 p.m. ET. The discussion will be accessible via a live webcast on the Company's website and will remain available for approximately 30 days post-event. LogicBio focuses on innovative genetic medicine solutions, including its GeneRide™ platform for gene insertion and sAAVy™ for optimized gene delivery, aimed at treating rare diseases across all age groups. For further details, visit their website.

LogicBio Therapeutics (Nasdaq: LOGC) reported financial results for the year ending December 31, 2021, showcasing a revenue increase to $5.4 million from $3.5 million in 2020, driven by collaboration revenues. R&D expenses rose to $28.2 million, while G&A expenses climbed to $16.2 million, contributing to a net loss of $40.0 million, or $1.24 per share. The company experienced a clinical hold on LB-001 after a serious adverse event, though it resolved. LogicBio maintains a cash position of $53.5 million, projected to fund operations through Q1 2023.

LogicBio Therapeutics (LOGC) announced that the FDA has placed a clinical hold on its Phase 1/2 SUNRISE trial of LB-001, a gene therapy for methylmalonic acidemia (MMA), due to safety concerns following serious adverse events in two pediatric patients. Despite successful dosing of four patients, including two who reported no drug-related issues, the trial's future is uncertain as LogicBio collaborates with the FDA for next steps. The company has suspended guidance on interim data until further clarity is achieved.